This study investigates whether vaginal estrogen treatment has an effect on hemostatic parameters in postmenopausal women. Blood samples are collected before and after 3 months treatment to assess changes in hemostasis.

This prospective cohort study includes 90 postmenopausal women aged ≥ 50, having vaginal atrophy symptoms and indication for treatment with vaginal estrogen tablets 10 µg at least 3 times a week for 3 months. Participants are divided into 2 study populations. Study population 1: 45 without a history of venous thromboembolic event and study population 2: 45 with a history of venous thromboembolic event.

Participation will involve 2 visits:

• First visit: prior the initiation of treatment an interview is carried out to assess inclusion criteria and information on demographics followed by blood sampling.
• Second visit: follow-up blood sampling after three months treatment. Hemostatic parameters will be assessed, comparing the blood samples at baseline with the follow-up blood sample.

Inclusion Criteria:

• Postmenopausal women aged ≥ 50
• Symptomatic vaginal atrophy
• Indication for standard treatment with vaginal estrogen tablets 10 µg at least three times a week
• Study population 1: without a history of venous thromboembolic event
• Study population 2: with a history of venous thromboembolic event

Exclusion Criteria:

• Unable to give written informed consent
• Does not speak Danish
• Current cancer treatment
• Current treatment with blood thinning medication (except plateletinhibitor)
• Current treatment with local or systematic estrogen
• Systemic inflammatory disease, liver disease or kidney disease